Literature DB >> 19547920

Sunitinib inducing tumor lysis syndrome in a patient treated for renal carcinoma.

Judith Michels1, Nathalie Lassau, Marine Gross-Goupil, Christophe Massard, Arnaud Mejean, Bernard Escudier.   

Abstract

Sunitinib is an oral antityrosine kinase inhibitor that has antiangiogenic and antitumor activities. It has been approved for the treatment of advanced RCC and for imatinib-refractory gastrointestinal stromal tumors (GIST). Tumor lysis syndrom can occur in solid tumors. We report a case of patient with metastatic RCC treated with sunitinib with a diagnosis of tumor lysis syndrome.

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19547920     DOI： 10.1007/s10637-009-9275-z

Source DB:  PubMed          Journal:  Invest New Drugs        ISSN： 0167-6997            Impact factor:   3.850


  9 in total

1.  Tumor lysis syndrome after treatment of a gastrointestinal stromal tumor with the oral tyrosine kinase inhibitor sunitinib.

Authors:  Philip J Saylor; Tony R Reid
Journal:  J Clin Oncol       Date:  2007-08-10       Impact factor: 44.544

Review 2.  Dynamic contrast-enhanced ultrasonography (DCE-US) with quantification of tumor perfusion: a new diagnostic tool to evaluate the early effects of antiangiogenic treatment.

Authors:  Nathalie Lassau; Linda Chami; Baya Benatsou; Pierre Peronneau; Alain Roche
Journal:  Eur Radiol       Date:  2007-12       Impact factor: 5.315

3.  Tumour lysis syndrome in a patient with renal-cell carcinoma treated with sunitinib malate.

Authors:  Theo Nicholaou; Rachel Wong; Ian D Davis
Journal:  Lancet       Date:  2007-06-09       Impact factor: 79.321

4.  Sunitinib versus interferon alfa in metastatic renal-cell carcinoma.

Authors:  Robert J Motzer; Thomas E Hutson; Piotr Tomczak; M Dror Michaelson; Ronald M Bukowski; Olivier Rixe; Stéphane Oudard; Sylvie Negrier; Cezary Szczylik; Sindy T Kim; Isan Chen; Paul W Bycott; Charles M Baum; Robert A Figlin
Journal:  N Engl J Med       Date:  2007-01-11       Impact factor: 91.245

5.  Prevention and treatment of hyperuricemia with rasburicase in children with leukemia and non-Hodgkin's lymphoma.

Authors:  Imre Rényi; Edit Bárdi; Erzsébet Udvardi; Gábor Kovács; Katalin Bartyik; Pál Kajtár; Péter Masát; Kálmán Nagy; Ilona Galántai; Csongor Kiss
Journal:  Pathol Oncol Res       Date:  2007-03-27       Impact factor: 3.201

Review 6.  Sunitinib: from rational design to clinical efficacy.

Authors:  Laura Q M Chow; S Gail Eckhardt
Journal:  J Clin Oncol       Date:  2007-03-01       Impact factor: 44.544

Review 7.  Avoiding dialysis in tumour lysis syndrome: is urate oxidase effective? - a case report and review of literature.

Authors:  Wan Yee Teo; Tsee Foong Loh; Ah Moy Tan
Journal:  Ann Acad Med Singapore       Date:  2007-08       Impact factor: 2.473

8.  Acute tumor lysis syndrome in a hemodialysis patient with diffuse large B cell lymphoma.

Authors:  Cheng-Jui Lin; Han-Hsiang Chen; Ruey-Kuen Hsieh; Yi-Chou Chen; Chih-Jen Wu
Journal:  Med Oncol       Date:  2008-09-03       Impact factor: 3.064

9.  Acute tumor lysis syndrome in solid tumors--a case report and review of the literature.

Authors:  L Baeksgaard; J B Sørensen
Journal:  Cancer Chemother Pharmacol       Date:  2003-02-28       Impact factor: 3.333
  9 in total
  7 in total

Review 1.  Evaluation of treatment response in patients with metastatic renal cell carcinoma: role of state-of-the-art cross-sectional imaging.

Authors:  Venkata S Katabathina; Nathalie Lassau; Ivan Pedrosa; Chaan S Ng; Srinivasa R Prasad
Journal:  Curr Urol Rep       Date:  2012-02       Impact factor: 3.092

2.  Pazopanib-related tumor lysis syndrome in metastatic clear cell renal cell carcinoma: a case report.

Authors:  Michael W van Kalleveen; Maudy Walraven; Mathijs P Hendriks
Journal:  Invest New Drugs       Date:  2018-02-20       Impact factor: 3.850

Review 3.  Tumor Lysis Syndrome: An Endless Challenge in Onco-Nephrology.

Authors:  Gabriela Lupușoru; Ioana Ailincăi; Georgiana Frățilă; Oana Ungureanu; Andreea Andronesi; Mircea Lupușoru; Mihaela Banu; Ileana Văcăroiu; Constantin Dina; Ioanel Sinescu
Journal:  Biomedicines       Date:  2022-04-28

4.  An unusual presentation of tumor lysis syndrome in a patient with advanced gastric adenocarcinoma: case report and literature review.

Authors:  Danica Maria Vodopivec; Jose Enrique Rubio; Alessia Fornoni; Oliver Lenz
Journal:  Case Rep Med       Date:  2012-05-27

5.  Tumor lysis syndrome in a patient with metastatic colon cancer after treatment with 5-fluorouracil/leucovorin and oxaliplatin: case report and literature review.

Authors:  Hyung Duk Kim; Kyung Sun Ha; In Sook Woo; Yun Hwa Jung; Chi Wha Han; Tae-Jung Kim
Journal:  Cancer Res Treat       Date:  2014-04-22       Impact factor: 4.679

6.  Fatal Tumour Lysis Syndrome Induced by Brigatinib in a Lung Adenocarcinoma Patient Treated With Sequential ALK Inhibitors: A Case Report.

Authors:  Yadong Wang; Tiange Wang; Jianchao Xue; Ziqi Jia; Xinyu Liu; Bowen Li; Ji Li; Xiaoguang Li; Weiwei Wang; Zhongxing Bing; Lei Cao; Zhili Cao; Naixin Liang
Journal:  Front Pharmacol       Date:  2021-12-20       Impact factor: 5.810

Review 7.  Tumor Lysis Syndrome in Solid Tumors: An up to Date Review of the Literature.

Authors:  Aibek E Mirrakhimov; Alaa M Ali; Maliha Khan; Aram Barbaryan
Journal:  Rare Tumors       Date:  2014-06-13
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.